IMPEDIMED LIMITED — Capital/Financing Update 2021

Mar 14, 2021

==> picture [230 x 55] intentionally omitted <==

15 March 2021

ASX ANNOUNCEMENT

NOTICE OF EXERCISE OF OPTIONS

Brisbane, Australia – ImpediMed Limited (ASX.IPD) confirms that in accordance with the prospectus issued for the 13 to 10 accelerated non-renounceable pro rata entitlement offer and announced on 2 April 2020 ( Entitlement Offer ), the final exercise date for the unlisted options ( Options ) issued under the Entitlement Offer is 31 March 2021. Any remaining Options not exercised by 31 March 2021 will automatically lapse and no longer be available for exercise.

This notice only applies to shareholders who participated in the April 2020 Entitlement Offer. Options were granted only to shareholders who participated in that offer.

Option holders who wish to exercise all or part of their Options must give the Company or the Share Registry a Notice of Exercise of Options form, together with payment of the exercise monies payable to the Company in connection with the Options being exercised [being $0.0375 (3.75 cents) per Option] prior to 5.00pm (Sydney time) on Wednesday, 31 March 2021.

To assist Option holders, a Notice of Exercise of Options form was sent to the address currently recorded with the Registry at Link Market Services. If you participated in the April 2020 entitlement issue and have not yet received an option entitlement form, please contact the company or Link Market Services for a replacement form. Contact details can be found below.

The Notice of Exercise of Options form is personalised and payment will be via a dedicated BPay facility. When you pay your funds utilising the personalized BPay facility, you are not required to submit the completed Notice of Exercise of Options form. If you do not have access to BPAY, please contact Link Market Services or the Company to make alternative arrangements.

The latest available market price of IPD ordinary shares was $0.11 as at the close of market 12 March 2021. The highest and lowest closing market prices of IPD ordinary shares during the 30 days immediately prior to this notice were $0.15 on 18 February 2021 and $0.098 on 8 March 2021, respectively. The option exercise price is $0.0375 cents. If you are unsure as to whether to participate in the Exercise of Options, please consult your investment, financial, taxation or other professional advisor.

The Company shall within five business days after the relevant Option Exercise Date, subject to receipt of a valid Notice of Exercise, issue Shares in respect of the Options exercised and dispatch a holding statement to the holder. Please refer to section 9.2 of the Prospectus for the full details on the terms and conditions of the Options. The Options will be exercised onto the existing SRN. You must contact your Broker, after the Options have been exercised, if you wish to transfer them onto your HIN.

Thank you for your ongoing support of ImpediMed.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

==> picture [159 x 38] intentionally omitted <==

Contact Details

All Registry communications to:

Link Market Services Limited Locked Bag A14 Sydney South NSW 1235 Australia Telephone: 1300 554 474 From outside Australia: +61 1300 554 474 Security Code: IPDOPT1 Website: www.linkmarketservices.com.au

ImpediMed Investor Relations: Mike Bassett Telephone: 0407 431 432 From outside Australia: +61 407 431 432 Email: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.